Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Falls Short On Challenge To Velphoro Formulation Patent

Israeli Firm Has A Second Case Pending, Although A Trial Date Is Not Set

Executive Summary

Teva has been shot down in its attempts to circumvent a key US patent shielding Vifor Pharma’s Velphoro dialysis drug.

You may also be interested in...



Teva Fails To Sidestep Eight Of Nine QuilliChew ER Patent Claims

A proposed Teva Pharmaceutical generic would infringe on multiple patents for Tris Pharma’s QuilliChew ER, a New Jersey district court has ruled.

Teva Fails On Quillivant XR Appeal – Five Years After Winning

Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.

Viatris And Sandoz May Market Injectafer Generic In US From 2026

After over two years of litigation, Vifor and American Regent have reached agreements with Viatris’ Mylan and Sandoz regarding their generic ferric carboxymaltose products, allowing both companies to bring rivals to market ahead of the expiry of certain US patents.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel